{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Hormone-Dependent", "query": { "condition": "Neoplasms, Hormone-Dependent" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Hormone-Dependent&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T01:34:44.415Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05262400", "title": "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors" ], "interventions": [ { "name": "PF-07220060 + PF-07104091 combination dose escalation", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + fulvestrant dose expansion", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + letrozole dose expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2022-03-14", "completion_date": "2026-08-23", "has_results": false, "last_update_posted_date": "2024-11-18", "last_synced_at": "2026-07-24T01:34:44.415Z", "location_count": 12, "location_summary": "Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05262400" }, { "nct_id": "NCT05288166", "title": "A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms", "Neoplasm Metastasis", "Urogenital Neoplasms", "Physiological Effects of Drugs", "Antineoplastic Agents", "Antineoplastic Agents, Hormonal", "Androgens", "Hormones", "Hormones, Hormone Substitutes, and Hormone Antagonists", "Abiraterone Acetate", "Steroid Synthesis Inhibitors", "Cytochrome P-450", "Enzyme Inhibitors", "Prednisone", "Prednisolone", "Cyclin-Dependent Kinase 4", "Cyclin-Dependent Kinase 6" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone or Prednisolone", "type": "DRUG" }, { "name": "Placebo for Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 925, "start_date": "2022-04-14", "completion_date": "2027-10", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-07-24T01:34:44.415Z", "location_count": 63, "location_summary": "Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more", "locations": [ { "city": "Prescott", "state": "Arizona" }, { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05288166" }, { "nct_id": "NCT03439735", "title": "Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Endocrine Therapy and a CDK 4/6 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 45, "start_date": "2018-07-20", "completion_date": "2026-11-01", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-07-24T01:34:44.415Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439735" }, { "nct_id": "NCT00267553", "title": "Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasms, Hormone-Dependent" ], "interventions": [ { "name": "Atamestane", "type": "DRUG" }, { "name": "toremifene", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intarcia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 200, "start_date": "2005-11", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2007-09-10", "last_synced_at": "2026-07-24T01:34:44.415Z", "location_count": 6, "location_summary": "Greenbrae, California • Saint Joseph, Michigan • Kansas City, Missouri + 3 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Saint Joseph", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Houston", "state": "Texas" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00267553" }, { "nct_id": "NCT00097344", "title": "The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasms, Hormone-Dependent" ], "interventions": [ { "name": "Atamestane", "type": "DRUG" }, { "name": "Toremifene", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Aromatase inhibition", "type": "DRUG" }, { "name": "Estrogen receptor blocker", "type": "DRUG" }, { "name": "Hormone therapy", "type": "PROCEDURE" }, { "name": "Endocrine therapy", "type": "PROCEDURE" }, { "name": "Antiestrogen therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Intarcia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 842, "start_date": "2004-12", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2007-08-23", "last_synced_at": "2026-07-24T01:34:44.415Z", "location_count": 49, "location_summary": "Mobile, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 46 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00097344" }, { "nct_id": "NCT00044291", "title": "Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasms, Hormone-dependent" ], "interventions": [ { "name": "atamestane", "type": "DRUG" }, { "name": "toremifene", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "aromatase inhibition", "type": "DRUG" }, { "name": "hormone therapy", "type": "PROCEDURE" }, { "name": "endocrine therapy", "type": "PROCEDURE" }, { "name": "antiestrogen therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Intarcia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 865, "start_date": "2002-06", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2015-07-31", "last_synced_at": "2026-07-24T01:34:44.415Z", "location_count": 17, "location_summary": "Lake Havasu City, Arizona • Tucson, Arizona • Greenbrae, California + 14 more", "locations": [ { "city": "Lake Havasu City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami Shores", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044291" }, { "nct_id": "NCT03155997", "title": "Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Standard Adjuvant Endocrine Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5637, "start_date": "2017-07-12", "completion_date": "2029-05", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-07-24T01:34:44.415Z", "location_count": 162, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155997" }, { "nct_id": "NCT06408168", "title": "Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone Receptor-positive Human Epidermal Growth Factor 2-negative", "Metastatic Invasive LObular Carcinoma" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Repotrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2024-08-08", "completion_date": "2025-12-08", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-07-24T01:34:44.415Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06408168" }, { "nct_id": "NCT06957691", "title": "Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostate Cancer (Adenocarcinoma)", "Prostate Cancer Metastatic Disease", "Prostate Cancer Recurrent", "Prostate Carcinoma", "Prostate Neoplasm", "Prostate Adenocarcinoma", "Prostate Cancer With Bone Metastasis", "Vasomotor Disturbance", "Vasomotor Symptoms", "Vasomotor Symptoms (VMS)", "Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men", "Vasomotor Symptoms; Hot Flashes", "Androgen Deprivation Therapy", "Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma", "Androgen-deprivation Therapy", "Hot Flashes", "Hot Flushes", "Hot Flushes and/or Sweats" ], "interventions": [ { "name": "fezolinetant - reference formulation", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shehzad Basaria, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "MALE", "summary": "40 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2026-01-14", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-07-24T01:34:44.415Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06957691" }, { "nct_id": "NCT03519178", "title": "A Study of PF-06873600 in People With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer" ], "interventions": [ { "name": "PF-06873600", "type": "DRUG" }, { "name": "Endocrine Therapy 1", "type": "DRUG" }, { "name": "Endocrine Therapy 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2018-03-07", "completion_date": "2024-10-30", "has_results": true, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-07-24T01:34:44.415Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03519178" } ] }